Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-12-19Clinical Trial Update: Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML [Phase 3]
This registry entry notes a Phase 3 study (SCRIPT-AML) evaluating a conditioning regimen for pediatric acute myeloid leukemia patients under…
-
CLINICAL_TRIALS research · 2024-12-18Clinical Trial Update: COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome [NA]
A feasibility study on coaching and prehabilitation for patients with acute myeloid leukemia and myelodysplastic syndromes, sponsored by Ins…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS [Phase 1]
A Phase 1 study of FD-001 in recurrent/refractory acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, and myelodysplastic syndro…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy [Phase 3]
Phase 3 clinical trial update comparing gilteritinib versus midostaurin in combination with induction, consolidation, and maintenance in adu…
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
A clinical trial is evaluating the PET imaging tracer 68Ga-DOTA-Siglec-9 in cancer patients. The study is currently enrolling by invitation …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-12-02Clinical Trial Update: Vyxeos for Induction of Low- or Intermediate-risk. [Phase 2]
This update reports on a Phase 2 study of Vyxeos (CPX-351) as induction therapy for adults with acute myeloid leukemia at low- or intermedia…
-
CLINICAL_TRIALS research · 2024-12-02Clinical Trial Update: Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML [Phase 2]
This update describes a Phase 2 trial comparing venetoclax plus azacitidine against intensive chemotherapy in fit patients with newly diagno…
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia [Phase 1]
This is a Phase 1 clinical trial evaluating CD70-CAR-NK cell therapy for relapsed/refractory T-cell lymphoma and relapsed/refractory acute m…
-
CLINICAL_TRIALS research · 2024-11-15Clinical Trial Update: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies [Phase 1]
Phase 1 study of VIP943 in adults with advanced CD123+ hematologic malignancies is currently recruiting, including acute myeloid leukemia, B…
-
CLINICAL_TRIALS research · 2024-11-15Clinical Trial Update: Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN [Phase 1]
Phase 1 clinical trial evaluating a CD123-targeted CAR-NK cell therapy for relapsed/refractory acute myeloid leukemia or blastic plasmacytoi…
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy [NA]
A clinical trial update evaluating venetoclax in combination with intensive therapy for acute myeloid leukemia patients who show low early p…
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia [Phase 1, Phase 2]
Phase 1/2 clinical trial investigating atorvastatin for mitigating cardiotoxicity in acute myeloid leukemia; the study is not yet recruiting…
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating sequential CAR-T cells targeting CD33 and CD123 in adults with acute myeloid leukemia is current…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax [Phase 2]
A Phase 2 clinical trial is evaluating a decitabine plus venetoclax combination for adults with acute myeloid leukemia arising from myelopro…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML [Phase 3]
Phase 3 trial evaluating gemtuzumab ozogamicin in combination with chemotherapy to assess minimal residual disease levels in adults with unt…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS [Phase 1]
Phase 1 trial update for PRGN-3006 adoptive cellular therapy targeting CD33-positive acute myeloid leukemia, including MRD-positive AML or h…
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy [Phase 2]
Phase 2 clinical trial update evaluating N-acetylcysteine (NAC) to promote hematopoietic recovery after chemotherapy in Acute Myeloid Leukem…
-
CLINICAL_TRIALS research · 2024-11-05Clinical Trial Update: Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
This completed retrospective chart review investigated treatment patterns and healthcare resource use in acute myeloid leukemia with or with…
-
CLINICAL_TRIALS research · 2024-11-05Clinical Trial Update: Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML [NA]
This clinical trial update indicates the study is currently RECRUITING to evaluate endothelial dysfunction and myocardial contractility in a…
-
CLINICAL_TRIALS research · 2024-11-04Clinical Trial Update: Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML [Phase 1, Phase 2]
Clinical trial update on the safety and efficacy of expanded, universal donor natural killer cells for relapsed/refractory acute myeloid leu…
-
CLINICAL_TRIALS research · 2024-10-29Clinical Trial Update: Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML) [Phase 2]
Phase 2 trial evaluating the addition of dexamethasone to intensive chemotherapy in older patients with acute myeloid leukemia.
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial investigating how AML molecular subtype and early measurable residual disease can guide initial treatment choices.
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia [Phase 3]
A Phase 3 clinical trial evaluating selinexor in combination with HAD or CAG regimens for relapsed or refractory acute myeloid leukemia is c…
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: CD155 Expression in Acute Myeloid Leukemia
This entry reports a completed clinical trial investigating CD155 expression in acute myeloid leukemia.
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. [Phase 1]
A Phase I, single-arm study evaluating donor NK cell infusion combined with low-dose interleukin-2 for relapse of acute myeloid leukemia aft…